Pharmaceuticals

A court ruling clears the way for Curium's targeted cancer drug, promising new hope for patients and shaking up the multi-billion-dollar radiopharmaceutical market.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

With enhanced GMP cell banking suites, Minaris integrates manufacturing and testing in Philadelphia, aiming to accelerate development in the booming CGT market.

RedHill Biopharma's new financing provides crucial cash, but the real story is in the warrants and the hunt for a strategic acquisition. A deep dive.

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.

Asimov's AI-driven synthetic biology platform partners with McGill's Goodman Cancer Institute, aiming to break the manufacturing bottleneck for complex drugs.

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

As CFO Dave Denton departs for the consumer goods sector, Pfizer taps a 20-year veteran for the interim role, signaling continuity amid a crucial post-acquisition phase.

Merck secures a pivotal FDA approval for its CAPVAXIVE vaccine, offering new hope for at-risk youth and challenging rivals in the high-stakes pneumococcal market.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

German biotech Mallia Aesthetics reports impressive results for its hormone-free hair serum, but the real story lies in its resilient, science-first strategy.

After three decades, a new class of therapy for a rare liver disease lands in Singapore, rewriting the rules of care by targeting patient suffering, not just lab results.

Iceland's Alvotech secured a crucial capital infusion. It's a high-stakes play to survive financial pressures and compete in the next wave of affordable medicine.

A new report projects the wellness market will hit $12.9T by 2031. This isn't just about yoga mats; it's a tech-fueled, Asia-led economic realignment.

After a 20-year drought, positive Phase 3 data for oral olorofim signals a safer, potent new option against a deadly fungus, promising a major market shake-up.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

Healthcare firm Cosmos Health is diversifying into the crowded skincare market with a DTC brand. Can its science-first approach disrupt the beauty industry?